Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Scotiabank lowered the firm’s price target on Keros Therapeutics (KROS) to $26 from $41 and keeps an Outperform rating on the shares. The firm is ...

ADAR1 Capital Management, LLC (together with its affiliates, "ADAR1"), the largest stockholder of Keros Therapeutics (Nasdaq: KROS) ("Keros" or the "Company") with approximately 13.3% of the ...

and a $200 million upfront payment from the Takeda Agreement is expected to provide a cash runway into 2029. Price Action: KROS stock is up 16.3% at $12.01 at the last check Thursday.

Keros Therapeutics’ KROS shares jumped 18.5% yesterday following an announcement that it is exploring strategic options, including a potential sale of the business. To aid the decision process ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Deal Dispatch: Harley-Davidson To Wipe Out? Plus, Prada's Versace Purchase Garners A Fashionable Price Things are hog wild at Harley-Davidson; Plus, Impresoft, Keros Therapeutics and Rivalry Corp ...

Investors were underwhelmed by the solid earnings posted by Keros Therapeutics, Inc. ( NASDAQ:KROS ) recently. We ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the ...